Please select the option that best describes you:

What is your preferred adjuvant regimen in upper tract urothelial carcinoma patients with GFR in the 40-50 range and positive circulating tumor DNA?  

Would you consider gemcitabine/carboplatin, split dose cisplatin or single agent immunotherapy